Severe Aortic Valve Stenosis: Symptoms, Biochemical Markers, and Global Longitudinal Strain.
B-type natriuretic peptides
left ventricular global longitudinal strain
severe aortic valve stenosis
Journal
Journal of cardiovascular echography
ISSN: 2211-4122
Titre abrégé: J Cardiovasc Echogr
Pays: India
ID NLM: 101562228
Informations de publication
Date de publication:
Historique:
received:
13
02
2020
revised:
23
04
2020
accepted:
18
09
2020
entrez:
15
1
2021
pubmed:
16
1
2021
medline:
16
1
2021
Statut:
ppublish
Résumé
According to the actual guidelines regarding severe aortic valve stenosis (AS), symptoms are the most important trigger for aortic valve replacement (AVR). However, the objective analysis of cardiological clinic can be confused, considering the aging population this disease affects and the comorbidities. Looking for an objective marker of disease, useful for scheduling the correct AVR, we researched the relation between some biochemical markers of left ventricular (LV) dysfunction and its global longitudinal strain. We analyzed 74 consecutive patients (82 ± 4 years) with severe AS. We identified 61 patients with symptoms (angina, dyspnea, and syncope) and 13 asymptomatic patients. The clinical and echocardiographic parameters were compared between these two groups. LV ejection fraction (LVEF), LV global longitudinal strain (LVGLS), NT-pro-B-type brain natriuretic peptide (BNP), troponin T (TNT), creatine kinase-MB (CPK-MB), and myoglobin were determined at the time of evaluation. Compared with the asymptomatic group, patients in the symptomatic group had a lower LVGLS ( Pro-BNP and LVGLS can be considered an objective marker of clinical severity of AS disease, useful for management and scheduling of AVR, especially in asymptomatic patients.
Sections du résumé
BACKGROUND
BACKGROUND
According to the actual guidelines regarding severe aortic valve stenosis (AS), symptoms are the most important trigger for aortic valve replacement (AVR). However, the objective analysis of cardiological clinic can be confused, considering the aging population this disease affects and the comorbidities.
OBJECTIVES
OBJECTIVE
Looking for an objective marker of disease, useful for scheduling the correct AVR, we researched the relation between some biochemical markers of left ventricular (LV) dysfunction and its global longitudinal strain.
MATERIALS AND METHODS
METHODS
We analyzed 74 consecutive patients (82 ± 4 years) with severe AS. We identified 61 patients with symptoms (angina, dyspnea, and syncope) and 13 asymptomatic patients. The clinical and echocardiographic parameters were compared between these two groups. LV ejection fraction (LVEF), LV global longitudinal strain (LVGLS), NT-pro-B-type brain natriuretic peptide (BNP), troponin T (TNT), creatine kinase-MB (CPK-MB), and myoglobin were determined at the time of evaluation.
RESULTS
RESULTS
Compared with the asymptomatic group, patients in the symptomatic group had a lower LVGLS (
CONCLUSIONS
CONCLUSIONS
Pro-BNP and LVGLS can be considered an objective marker of clinical severity of AS disease, useful for management and scheduling of AVR, especially in asymptomatic patients.
Identifiants
pubmed: 33447506
doi: 10.4103/jcecho.jcecho_13_20
pii: JCE-30-154
pmc: PMC7799072
doi:
Types de publication
Journal Article
Langues
eng
Pagination
154-161Informations de copyright
Copyright: © 2020 Journal of Cardiovascular Echography.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Int J Cardiol. 2018 May 1;258:262-268
pubmed: 29452989
J Heart Valve Dis. 2012 May;21(3):331-6
pubmed: 22808834
J Am Soc Echocardiogr. 2009 Jan;22(1):1-23; quiz 101-2
pubmed: 19130998
Circ Cardiovasc Imaging. 2012 Sep 1;5(5):613-20
pubmed: 22869821
J Am Soc Echocardiogr. 2017 Aug;30(8):727-735.e1
pubmed: 28599826
Int J Cardiol. 2017 Mar 1;230:371-377
pubmed: 28062138
Echocardiography. 2018 Aug;35(8):1077-1084
pubmed: 29663506
Eur Heart J. 1988 Apr;9 Suppl E:19-23
pubmed: 2969811
Biomarkers. 2016;21(4):316-27
pubmed: 26900722
Br Heart J. 1990 Apr;63(4):215-20
pubmed: 2140044
J Am Coll Cardiol. 2017 Jul 11;70(2):252-289
pubmed: 28315732
Eur Heart J Cardiovasc Imaging. 2016 Apr;17(4):412
pubmed: 26983884
Circ Cardiovasc Imaging. 2014 Nov;7(6):938-45
pubmed: 25320287
Nat Rev Cardiol. 2011 Mar;8(3):162-72
pubmed: 21263455
Heart. 2006 Sep;92(9):1194-7
pubmed: 16251227
Echocardiography. 2018 Dec;35(12):1909-1914
pubmed: 30376590
Eur Heart J. 2009 Dec;30(24):3037-47
pubmed: 19726436
Circulation. 2003 Apr 15;107(14):1884-90
pubmed: 12668523
Am J Cardiol. 2005 Nov 15;96(10):1445-8
pubmed: 16275196
J Am Coll Cardiol. 1995 Jul;26(1):195-202
pubmed: 7797752
Circulation. 2007 Jun 5;115(22):2848-55
pubmed: 17515464
N Engl J Med. 2000 Aug 31;343(9):611-7
pubmed: 10965007
Clin Physiol. 1992 Jul;12(4):443-52
pubmed: 1505166
J Am Soc Echocardiogr. 2011 Sep;24(9):984-91
pubmed: 21570253
J Am Coll Cardiol. 2014 May 20;63(19):2016-25
pubmed: 24657652
Can J Cardiol. 2014 Sep;30(9):962-70
pubmed: 24986049
Ann Thorac Surg. 2014 Mar;97(3):803-9
pubmed: 24200400
Circulation. 2004 May 18;109(19):2302-8
pubmed: 15117847
J Am Heart Assoc. 2016 Jan 05;5(1):
pubmed: 26732551
J Am Coll Cardiol. 1993 Apr;21(5):1220-5
pubmed: 8459080
Virchows Arch. 1997 Oct;431(4):265-73
pubmed: 9368664
Br Heart J. 1981 Mar;45(3):248-63
pubmed: 7008815